CSL on Sunday announced that its investigational cholesterol efflux enhancer CSL112 failed the Phase III AEGIS-II trial, unable to significantly improve outcomes in patients who had suffered a heart attack.
Featured Posts
Metagenomi shares dropped 31% on Friday afternoon in a disappointing debut on the Nasdaq Global Select Market, highlighting the potential perils faced by preclinical biotechs seeking to go public, according to Seeking Alpha.
Two Florida courts last week ruled in Novo Nordisk’s favor in its legal battle against wellness clinics and compounding pharmacies for marketing counterfeit or compounded versions of its popular weight-loss drug semaglutide.
Bayer’s CEO said on Friday that the healthcare and crop chemicals group continues to firmly back its glyphosate weedkiller even after a recent courtroom loss in U.S. litigation over an alleged carcinogenic effect.
Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared with rival shots from GSK and Pfizer.
Takeda will launch global Phase III trials of its investigational oral ORX2 agonist TAK-861 in narcolepsy type 1 in the first half of fiscal year 2024 and abandon the candidate’s development in narcolepsy type 2.
The CEOs of Bristol Myers Squibb, Johnson & Johnson and Merck testified Thursday before the Senate health committee, defending the high U.S. prices that Americans pay for prescription drugs compared to other countries based on patient value and the need to fund innovation and R&D costs.
Neurona Therapeutics on Thursday announced that it has secured $120 million in funding, which will help it advance its pipeline of investigational off-the-shelf cell therapies.
BioNTech is making moves in early 2024 to strengthen its CAR T pipeline, with a $250 million licensing and manufacturing deal announced Thursday with Autolus Therapeutics to advance the companies’ respective programs.
The European Medicines Agency is investigating the potential impacts that Novo Holdings’ $16.5 billion acquisition of contract manufacturing giant Catalent will have on drug supply, according to reporting Wednesday by Reuters.